Why the study?
Definitive evidence of a survival benefit from viral presence-guided immunomodulation is lacking, and divergence remains between guideline recommendations and clinical practice regarding empirical immunosuppression in acute lymphocytic myocarditis.
Does viral presence-guided immunomodulation improve survival compared to empirical therapy in patients with acute lymphocytic myocarditis?
Does viral presence-guided immunomodulation improve survival compared to empirical therapy in patients with acute lymphocytic myocarditis?
This review highlights the gap between guideline recommendations for viral PCR-guided immunosuppression in acute lymphocytic myocarditis and the lack of definitive evidence supporting its survival benefit.
No takes yet. Share an insight, caveat, or question.
Caution against routine viral PCR-guided immunosuppression in myocarditis; leaves open the need for RCTs to establish survival benefit.
Sinagra et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: